Kisqali

ribociclib-shows-higher-dose-adjustments-than-palbociclib-in-study

Ribociclib Shows Higher Dose Adjustments Than Palbociclib in Study

Editorial 20 December, 2025

In a recent analysis conducted at a single center, ribociclib (Kisqali; Novartis) was found...

novartis-increases-sales-projections-for-key-oncology-drugs

Novartis Increases Sales Projections for Key Oncology Drugs

Editorial 20 November, 2025

Swiss pharmaceutical giant Novartis AG has significantly raised its sales projections for two of...

cdk4-6-inhibitors-advance-treatment-strategies-in-breast-cancer

CDK4/6 Inhibitors Advance Treatment Strategies in Breast Cancer

Editorial 30 August, 2025

Recent developments in the treatment of hormone receptor-positive (HR+) metastatic breast cancer have underscored...